Patient reported outcomes interfering with daily activities in prostate cancer patients receiving antineoplastic treatment

Figures & data

Figure 1. Graph illustrating percentage of PRO-CTCAE responses >0 for the four treatments across symptoms interfering with usual activities.

Table 1. PRO-CTCAE attributes and item structures [5,50].

Frequency	Severity	Interference	Amount	Presence/Absence
In the last 7 days how often did you have ____?	In the last 7 days, what was the severity of your ______ at its worst?	In the last 7 days how much did _____ interfere with your usual or daily activities?	In the last 7 days, did you have any _____?	In the last 7 days did you have any ____ ?
Never Rarely Occasionally Frequently Almost constantly	None Mild Moderate Severe Very severe	Not at all A little bit Somewhat Quite a bit Very much	Not at all A little bit Somewhat Quite a bit Very much	No Yes

Figure 2. Graph illustrating percentage of PRO-CTCAE responses grade 3 or above, for the four treatments across symptoms interfering with usual activities.

Figure 3. Top left shows percentage of patients receiving docetaxel with CTCAE score >0 published by Tannock et al. and percentage of patient responses with PRO-CTCAE score >0 (green columns) from our dataset. Top right shows percentage of patients receiving radium-223 with CTCAE score >0 published by Parker et al. and percentage of patient responses with PRO-CTCAE score >0 (green columns) from our dataset. Bottom left shows percentage of patients receiving cabazitaxel with CTCAE score >0 published by Bono et al. and percentage of patient responses with PRO-CTCAE score >0 (green columns) from our dataset. Bottom right graph shows percentage of patients receiving abiraterone with CTCAE score >0 published by Fizazi et al. (light green columns represents our PRO-CTCAE responses but are based on only 5 responses by two patients).

Table 2. Comparing percentage of PRO-CTCAE responses interfering with usual or daily activities, and matching CTCAE reported by registration studies.

PRO-CTCAE/CTCAE	Docetaxel all grades/grade >3		Cabazitaxel all grades/grade >3		Radium-223 all grades/grade 3		Abiraterone all grades/grade 3
	PRO	CTCAE [26]	PRO	CTCAE [27]	PRO	CTCAE [28]	PRO	CTCAE [29]
Watery eyes/Watering eyes	44%/5%	10%/NA	20%/0%	NA	40%/5%	NA	0%	NA
Abdominal pain	16%/5%	NA	12%/0%	12%/2%	36%/10%	NA	40%/0%	13%/2%
Fatigue	89%/22%	53%/5%	58%/30%	37%/5%	82%/17%	26%/4%/1%*	80%/0%	47%/9 %/<1%*
General pain/Pain	52%/13%	NA	25%/3%	5%/1%	58%/3%	NA	80%/0%	5%/<1%
Decreased appetite/Anorexia	25%/5%	17%	14%/2%	NA	36%/2%	23%/2%	0%	NA
Joint pain/Arthralgia	30%/7%	NA	24%/3%	11%/1%	31%/0 %	50%/20%/1%*	80%/0%	30%/5%
Muscle pain/Myalgia	36%/9%	14%	24%/2%	8%/2%	35%/2%	NA	60%/0%	20% /3%/<1%*
Shortness of breath/Dyspnea	44%/7%	15%	20%/0%	12%/1%	40%/8%	8%/2%/1%*	0%	15%/2%/<1%*
Swelling/Edema	28 %/0%	19%	11%/3%	NA	12%/7%	13%/2%	20%/0%	33%/2%/<1%*
Cough	29 %/0%	NA	8%/0%	NA	14 %/2%	NA	20 %/0%	NA
Numbness/Sensory neuropathy	35%/4%	30%	20%/0%	NA	34%/5%	NA	40%/0%	NA

*Grade 4/5 if reported.

PRO column: data collected in this study; CTCAE column: toxicity data from relevant registration studies.

Basch E, Reeve BB, Mitchell SA, et al. Development of the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.

 PubMedGoogle Scholar

Taarnhøj GA, Kennedy FR, Absolom KL, et al. Comparison of EORTC QLQ-C30 and PRO-CTCAETM Questionnaires on six symptom items. J Pain Symptom Manage. 2018;56(3):421–429.

 PubMed Web of Science ®Google Scholar

Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.

 PubMed Web of Science ®Google Scholar

De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.

 PubMed Web of Science ®Google Scholar

Parker C, Nilsson D, Heinrich S, Helle SI, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.

 PubMed Web of Science ®Google Scholar

Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.

 PubMed Web of Science ®Google Scholar